Abstract Following the European Forum for Research and Education in Allergy and Airway
Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps …

Introduction The recent approval of Dupilumab has profoundly revolutionized the
management of patients affected by severe and recalcitrant Chronic Rhinosinusitis with …

Objective This study aimed to evaluate the effectiveness and safety of dupilumab during the
first year of treatment in a real-life setting, focusing on improvement in nasal polyp score …

Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease
with multifactorial etiopathogenesis. This study investigated the recurrence rate and risk …

Background: Loss of smell is a part of the diagnostic criteria for CRSwNP. Although the
mechanistic understanding is poor, inhibition of IL-4Rα and IL-4/IL-13 signaling improves …

Introduction Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit,
effectively blocks both IL-4 and IL-13 mediated pathways. Its introduction has represented a …

Background. Dupilumab represents the first approved biological for severe uncontrolled
chronic rhinosinusitis with nasal polyps (CRSwNP). Objective. Aim of this paper is to provide …

Germinal center (GC)-derived memory B cells (MBCs) are critical for humoral immunity as
they differentiate into protective antibody-secreting cells during re-infection. GC formation …

Nonsteroidal anti-inflammatory drug (NSAID)–exacerbated respiratory disease (NSAID-
ERD), the clinical triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and …

Purpose Historically managed with intranasal corticosteroids (INCS) and endoscopic sinus
surgery (ESS), type-2 Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) treatment was …